Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 41

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 41
---
 and (ii) adopt new
Articles of Association, which made consequential amendments to the existing Articles of Association of the Company to reflect the June
Subdivision. As is standard for deferred shares, each D deferred share has very limited rights and is effectively valueless. The D deferred
shares have the rights and restrictions as set out in the Articles of Association and do not entitle the holder thereof to receive notice
of or attend and vote at any general meeting of the Company or to receive a dividend or other distribution.

Warrant Inducement

On May 15, 2025, we entered
into the 2025 Warrant Agreements with certain Holders of our outstanding Series E Warrants, Series H Warrants, Series J Warrants, and
Series K Warrants issued in prior transactions, pursuant to which the Holders agreed to exercise certain of such warrants in exchange
for a reduction in exercise price of each warrant to $0.31 per share. An aggregate of 200,433 warrants were exercised for aggregate gross
proceeds of approximately $62,000, before estimated offering expenses. We did not issue new warrants to replace the warrants that were
exercised.

eRapa Granted Orphan Drug Designation in Europe

On May 12, 2025, we announced
that the European Commission had granted Orphan Drug Designation for eRapa in FAP. Orphan Drug Designation in the European Union is granted
by the European Commission based on a positive opinion issued by the EMA Committee for Orphan Medicinal Products. It is intended to encourage
the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases. If approved
for marketing, this designation will provide 10 years of marketing exclusivity and also provide special incentives for sponsors, including
eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees.

For more information on recent
developments with respect to eRapa, see “—Company Overview.”

Contingent Liability

As previously disclosed in
the Notes to the Consolidated Unaudited Interim Financial Information for the six-month period ended June 30, 2025, we were involved in
a dispute with a former advisor regarding fees. The dispute was resolved through a settlement, the terms of which included a payment made
to the former advisor on September 29, 2025.

Our Strategy

In early 2023, we decided
to re-position the Company as therapeutics (as opposed